Investigating the Effect of Onopordon Acanthium Seed on Primary Hypertension Reduction in Patients under Treatment by Losartan

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013020712391N1

Enrollment

Registered

2013-04-14

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hypertension. Essential (primary) hypertension

Interventions

Intervention 1: All patients in interfering group take 50mg Losartan and also a capsule containing Onopordon Acanthium seeds extract orally once a day. Intervention 2: All patients in control group, t

Treatment - Drugs

Placebo

All patients in interfering group take 50mg Losartan and also a capsule containing Onopordon Acanthium seeds extract orally once a day.

All patients in control group, take 50mg Losartan and also placebo which is designed this study orally once a day.

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Aged between 30 and 60; SBP>= 140; DBP >= 90 mmHg; Patient under treatment by Losartan (50 mg); Exclusion Criteria: Existence of malignant hypertension, i.e. blood pressure higher than 200/140 mmHg which needs multi-drug treatment or emergency IV drug infusion to control blood pressure; History of secondary hypertension ; Existence of end organ damages (EOD); Sudden increase of blood pressure to greater than 15 mmHg at any time during the study; Existence of any kind of cardiac arrhythmias; Symptomatic valvular heart diseases (except mitral valve prolapse); Liver function disorders; Pregnancy and lactation; Cured or uncured malignancy during the last 5 years; Serum potassium >5.2 or <3.5 mEq/L in the first visit; Drug or alcohol usage background; Any kind of disorder (medical or surgical) which can interfere the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Systolic Blood Pressure. Timepoint: Beginning of the project, End of the second week, end of the fourth week, end of the sixth week, end of the eighth week. Method of measurement: Measuring by mercury sphygmomanometer in millimetres of mercury (mmHg).;Diastolic Blood Pressure. Timepoint: Beginning of the project, End of the second week, end of the fourth week, end of the sixth week, end of the eighth week. Method of measurement: Measuring by mercury sphygmomanometer in millimetres of mercury (mmHg).	—

Measure

Time frame

Systolic Blood Pressure. Timepoint: Beginning of the project, End of the second week, end of the fourth week, end of the sixth week, end of the eighth week. Method of measurement: Measuring by mercury sphygmomanometer in millimetres of mercury (mmHg).;Diastolic Blood Pressure. Timepoint: Beginning of the project, End of the second week, end of the fourth week, end of the sixth week, end of the eighth week. Method of measurement: Measuring by mercury sphygmomanometer in millimetres of mercury (mmHg).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Roshanak Ghods

Tehran University of Medical Sciences

ghods_r@razi.tums.ac.ir+98 21 7750 4066

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026